Student Loans
An education loan is a form of financial aid that must be repaid, with interest. (Scholarships, on the other hand, do not have to be repaid.)
Education loans come in three major categories: student loans (e.g., Stafford and Perkins loans), parent loans (e.g., PLUS loans) and private student loans (also called alternative student loans). A fourth type of education loan, the consolidation loan, allows the borrower to lump all of their loans into one loan for simplified payment. A recent innovation is peer-to-peer education loans. More than $100 billion in federal education loans and $10 billion in private student loans are originated each year.
Since July 1, 2010, all new federal education loans have been made through the Direct Loan program. The loans are made through the college's financial aid office with funds provided by the US Department of Education. This includes the Federal Parent PLUS loan in addition to student loans. The terms of the Federal Stafford, PLUS and Consolidation loans are similar to the terms of the federal education loans previously available through the federally-guaranteed student loan programs. However, the interest rate on the Federal Direct PLUS loan is lower (7.9% vs. 8.5%) and the approval rate is higher.
Making payments of at least the new interest that accrues during the in-school and grace periods avoids negative amortization. This can save borrowers money and help them pay off the debt sooner that borrowers who defer payments of principal and interest.
Federal law sets the maximum interest rates and fees that lenders may charge for federally-guaranteed loans. Nothing prevents a lender from charging lower fees. Many lenders offer a variety of student loan discounts to attract borrowers.
Few students can afford to pay for college without some form of education financing. Two-thirds (65.6%) of 4-year undergraduate students graduated with a Bachelor's degree and some debt in 2007-08, and the average student loan debt among graduating seniors was $23,186 (excluding PLUS Loans but including Stafford, Perkins, state, college and private loans). Among graduating 4-year undergraduate students who applied for federal student aid, 86.3% borrowed to pay for their education and the average cumulative debt was $24,651. (For just federal student loan debt, excluding PLUS Loans, the figures are 61.6% and $17,878.) Average cumulative debt increased by 5.6% or $1,139 a year since 2003-04. When one includes PLUS loans in the total, 66.0% of 4-year undergraduate students graduated with some debt in 2007-08, and the average cumulative debt incurred was $27,803. (About two in fifteen (13.5%) of parents borrow PLUS loans for their children's college education, with a cumulative PLUS loan debt of $23,298.)
These figures were calculated using the data analysis system for the 2007-2008 National Postsecondary Student Aid Study (NPSAS) conducted by the National Center for Education Statistics at the US Department of Education. (For comparison, cumulative education debt statistics from the 2003-2004 NPSAS are also available.) The 2007-2008 NPSAS surveyed 114,000 undergraduate students and 14,000 graduate and professional students. These statistics are not necessarily available from published NPSAS reports.
The median cumulative debt among graduating Bachelor's degree recipients at 4-year undergraduate schools was $19,999 in 2007-08. One quarter borrowed $30,526 or more, and one tenth borrowed $44,668 or more. 9.5% of undergraduate students and 14.6% of undergraduate student borrowers graduating with a Bachelor's degree graduated with $40,000 or more in cumulative debt in 2007-08. This compares with 6.4% and 10.0%, respectively, for Bachelor's degree recipients graduating with $40,000 or more (2008 dollars) in cumulative debt in 2003-04.
The following table shows the percentage of students borrowing and average cumulative debt per borrower (excluding Parent PLUS Loans) at graduation according to type of educational institution but not restricted by degree program.
Undergraduate Education Debt
(Excluding Parent PLUS Loans)
Institution Level & Control Percent Borrowing Cumulative Debt
Overall Total (4, 2 and < 2 year) 58.8% $18,625
Public 49.4% $16,369
Private Non-Profit 69.7% $26,683
Private For-Profit 93.1% $17,162
4-year Total 66.5% $22,656
4-year Public 61.1% $19,839
4-year Private Non-Profit 70.6% $27,349
4-year Private For-Profit 97.0% $24,635
2-year Total 44.8% $12,307
2-year Public 37.2% $10,444
2-year Private Non-Profit 64.0% $14,790
2-year Private For-Profit 97.6% $17,310
< 2-year Total 74.7% $10,172
< 2-year Public 36.1% $10,321
< 2-year Private Non-Profit 45.0% $10,990
< 2-year Private For-Profit 86.0% $10,123
As noted in Default Rates by Institution Level vs. Degree Program, however, institution level (4-year, 2-year and less-than-2-year) does not correlate well with degree program, especially at for-profit colleges. The following table shows cumulative debt at graduation by institution control and undergraduate degree program. Notice how the average debt for Bachelor's degree recipients is much higher at for-profit colleges than the average debt at graduation at 4-year for-profit colleges. More than two-fifths of degrees at 4-year for-profit colleges are Associate's degrees, compared with less than 5% at non-profit and public 4-year colleges, yielding a lower average debt at graduation when measured by institution level as opposed to degree program.
Undergraduate Education Debt
Institution Control and
Degree Program Percent
Borrowing Average
Cumulative
Debt Median
Cumulative
Debt
(Just Borrowers) Median
Cumulative
Debt
(All Students)
Bachelor's Degree 65.2% $23,118 $19,999 $10,500
Public 61.2% $20,040 $17,500 $6,998
Private Non-Profit 70.5% $27,535 $22,374 $16,115
Private For-Profit 96.0% $32,909 $32,625 $31,186
Associate's Degree 47.1% $13,289 $10,000 $0
Public 38.9% $10,574 $7,668 $0
Private Non-Profit 71.1% $19,294 $16,130 $10,000
Private For-Profit 97.8% $19,681 $18,783 $18,415
Certificate 63.2% $11,302 $9,000 $4,804
Public 32.0% $9,754 $6,625 $0
Private Non-Profit 49.5% $15,071 $10,000 $0
Private For-Profit 89.9% $11,573 $9,858 $8,797
The following table shows the percentage of students borrowing and average cumulative debt per borrower (including Parent PLUS Loans) at graduation according to type of educational institution but not restricted by degree program. (The NPSAS includes separate variables for cumulative student education debt and cumulative parent education debt, but not a combined overall education debt variable. Calculating a combined value requires disaggregating the student and parent education debt data by the cross product of students graduating with and without student and parent education debt, then recombining the results. This process adds a slight amount of error to the figures.)
Undergraduate Education Debt
(Including Parent PLUS Loans)
Institution Level & Control Percent Borrowing Cumulative Debt
Overall Total (4, 2 and < 2 year) 59.0% $21,894
Public 49.6% $18,927
Private Non-Profit 70.0% $33,330
Private For-Profit 93.2% $19,157
4-year Total 66.8% $27,041
4-year Public 61.5% $23,227
4-year Private Non-Profit 70.9% $34,212
4-year Private For-Profit 97.0% $27,510
2-year Total 44.8% $13,703
2-year Public 37.3% $11,560
2-year Private Non-Profit 64.1% $17,157
2-year Private For-Profit 97.6% $19,402
< 2-year Total 74.8% $11,161
< 2-year Public 36.1% $10,877
< 2-year Private Non-Profit 45.0% $10,990
< 2-year Private For-Profit 86.2% $11,203
Bachelor's Degree 65.6% $27,708
Public 61.6% $23,494
Private Non-Profit 70.8% $34,572
Private For-Profit 96.0% $35,753
Associate's Degree 47.1% $14,907
Public 38.9% $11,640
Private Non-Profit 71.2% $21,406
Private For-Profit 97.8% $22,738
Certificate 63.2% $12,524
Public 32.0% $10,833
Private Non-Profit 44.0% $11,772
Private For-Profit 90.0% $12,712
Graduate and professional students borrow even more, with the additional cumulative debt for a graduate degree typically ranging from $30,000 to $120,000. The median additional debt is $25,000 for a Master's degree, $52,000 for a doctoral degree and $79,836 for a professional degree. A quarter of graduate and professional students borrow more than $42,898 for a Master's degree, more than $75,712 for a doctoral degree and more than $118,500 for a professional degree. At the 90th percentile cumulative debt for graduate and professional degrees exceeds $59,869 for a Master's degree, $123,650 for a doctoral degree and $159,750 for a professional degree.
The following table shows the percentage borrowing and average amount of cumulative debt per borrower among graduating students according to degree program. It provides the amounts borrowed for just the graduate education and also the combined totals for undergraduate and graduate education. Undergraduate students who graduate with a Bachelor's degree and no debt are 1.7 times more likely to enroll in graduate and professional school than Bachelor's degree recipients who graduate with some debt.
All Students Graduate Education Debt All Education Debt
(Grad & Undergrad)
Graduate & Professional Degree Programs Percent Borrowing Cumulative Debt Percent Borrowing Cumulative Debt
Total 56.4% $40,297 69.6% $47,503
Master's Degree 55.2% $31,031 69.4% $40,208
Doctoral Degree 45.8% $57,860 56.3% $58,967
Professional Degree 86.2% $87,308 87.9% $98,711
Master of Business Administration (MBA) 55.5% $31,927 68.9% $41,676
Master of Social Work (MSW) 72.3% $35,516 77.7% $49,017
Master of Science (MS) 49.8% $30,684 63.5% $40,362
Master of Arts (MA) 60.8% $29,975 73.7% $40,500
Master of Education or Teaching 55.9% $26,487 74.5% $35,946
PhD 35.4% $44,995 48.0% $45,455
EdD 65.1% $43,812 73.3% $44,880
Law (LLB or JD) 88.6% $80,081 88.6% $92,937
Medicine or Osteopathic Medicine 81.9% $119,424 83.2% $127,272
Pharmacy (PharmD) 82.2% $63,412 85.0% $81,838
The following table shows the percentage of graduating students at graduate and professional institutions who applied for federal student aid and graduated with debt and the average cumulative debt at graduation according to degree program. This demonstrates that graduating with debt is unavoidable for students pursuing degrees in law, medicine or business who need to apply for federal student aid.
Submitted FAFSA Graduate Education Debt All Education Debt
(Grad & Undergrad)
Graduate & Professional Degree Programs Percent Borrowing Cumulative Debt Percent Borrowing Cumulative Debt
Total 94.3% $46,865 96.9% $62,285
Master's Degree 94.5% $34,741 97.7% $51,223
Doctoral Degree 82.8% $73,885 85.0% $85,366
Professional Degree 99.4% $92,575 99.9% $105,705
Master of Business Administration (MBA) 98.2% $34,691 98.9% $53,779
Master of Social Work (MSW) 91.9% $36,924 91.9% $54,020
Master of Science (MS) 95.2% $34,824 98.3% $52,102
Master of Arts (MA) 94.0% $34,357 97.4% $50,102
Master of Education or Teaching 92.6% $31,540 96.8% $49,286
PhD 67.5% $58,353 72.0% $69,754
EdD 94.5% $51,695 94.5% $61,121
Law (LLB or JD) 99.9% $82,601 99.9% $95,914
Medicine or Osteopathic Medicine 100.0% $126,152 100.0% $136,474
Pharmacy (PharmD) 100.0% $66,319 100.0% $88,648
Grants, scholarships, work-study and other forms of gift aid just do not cover the full cost of a college education. Many students find that they must supplement their savings with government and private loans. The Federal education loan programs offer lower interest rates and more flexible repayment plans than most consumer loans, making them an attractive way to finance your education. You can also deduct up to $2,500 in student loan interest even if you don't itemize deductions on your income tax return.
The interest rate on the Stafford Loan for new loans first disbursed on or after July 1, 2006 is a fixed rate of 6.8%. The same rate applies to the in-school, grace and repayment periods. (A lower interest rate is available on subsidized Stafford loans for undergraduate students for loans first disbursed on or after July 1, 2008 through June 30, 2012. The rate in 2008-09 is 6.0%, then 5.6% in 2009-10, then 4.5% in 2010-11 and 3.4% in 2011-12 and returning to 6.8% for new loans in 2012-13 onward.) The interest rate on new PLUS Loans first disbursed after July 1, 2006 is a fixed rate of 8.5% in the FFEL program and 7.9% in the Direct Loan program. Starting July 1, 2010, all new federal education loans have been made through the Direct Loan program.
The interest rates on existing variable rate Stafford and PLUS loans will continue to change annually on July 1, based on the last 91-day T-bill auction in May. Borrowers can lock in the current rate on their variable rate loans by consolidating them. Borrowers can compare the current and new rates between the end of May and the end of June to decide whether it is worthwhile to consolidate before or after the rate change.
Borrowers may be concerned by the possible impact of the subprime credit crisis on the cost and availability of federal and private student loans. Federal loans will remain available, although loan discounts will likely be reduced significantly. A higher minimum balance may be required to consolidate. Private student loans will likely have stricter eligibility restrictions, requiring a higher credit score or a cosigner. There may be increases in the interest rates and fees on private student loans. Lenders will encourage borrowers to make payments of interest while they are in school.
Many student loan providers offer low cost government and private loans with consistently high quality servicing and flexible repayment terms. FinAid maintains a list of education lenders, guarantee agencies, servicers and secondary markets who previously offered federal and may currently offer private student loans, as well as advice on preferred lender lists and choosing a lender and tips on identifying the lenders that currently hold or service your loans.
Borrowers of federal student loans will be required to undergo entrance and exit counseling before receiving a loan and before graduation. This loan counseling is often provided through interactive web sites.
Loan forgiveness programs (in which the borrower's loans are paid off in exchange for volunteer work, public service or military service) offer an option for easy repayment. Loan Cancellation and Discharge Forms can be found on the US Department of Education web site.
Also, FinAid provides numerous calculators that can help you better understand your borrowing options. The loan calculators offer estimates of monthly loan payments, estimates of the amount of debt you can afford to repay, an analysis of the cost of capitalizing the interest and tools for comparing loan costs.
Use FinAid's Student Loan Checklist to keep track of your student loans.
Some students, because they do not have prior experience with debt and loan amortization, do not appreciate how much their loans will cost them. FinAid provides some tips concerning calculating the cost of interest.
If you are about to start repaying your student loans, or are already in repayment, the quick reference guide on repaying student loans provides four pages of information and advice about managing education debt. (A PowerPoint Presentation and handouts on repaying student loans are also available.)
Tuesday, December 14, 2010
स्टुडेंट loans
Most college or university students can secure Stafford student loans to assist with their financial needs, so what are you waiting for? Start now and find a Stafford Loan through StudentLoans.com.
Stafford Loans are the most widely used, low-cost education loan available from the United States Federal government, and Stafford Loans are a great way for you to secure the extra financial aid you need in order to meet your needs for college, university or trade school.
Stafford loans carry a low, fixed interest rate which is set by the Federal government. For undergraduate students, the interest rate for subsidized Stafford loans is 4.50%. For graduate students, the federal stafford loan interest rate is 6.8%. These rates are in effect from July 1, 2010 through June 30, 2011. for an explanation of the different eligibility requirements, terms and conditions for the subsidized (need based loan) vs. unsubsidized (not based on financial need) Stafford loan.
Stafford Student Loan Benefits
There are additional benefits of federal Stafford loans:
The interest may be tax deductible.
There is no prepayment penalty.
You can consolidate your federal Stafford loans to benefit from one convenient payment and potentially lower your monthly payments.www.staffordloan.com
Stafford Loans are the most widely used, low-cost education loan available from the United States Federal government, and Stafford Loans are a great way for you to secure the extra financial aid you need in order to meet your needs for college, university or trade school.
Stafford loans carry a low, fixed interest rate which is set by the Federal government. For undergraduate students, the interest rate for subsidized Stafford loans is 4.50%. For graduate students, the federal stafford loan interest rate is 6.8%. These rates are in effect from July 1, 2010 through June 30, 2011. for an explanation of the different eligibility requirements, terms and conditions for the subsidized (need based loan) vs. unsubsidized (not based on financial need) Stafford loan.
Stafford Student Loan Benefits
There are additional benefits of federal Stafford loans:
The interest may be tax deductible.
There is no prepayment penalty.
You can consolidate your federal Stafford loans to benefit from one convenient payment and potentially lower your monthly payments.www.staffordloan.com
क्रेडिट बोर्रोविंग दीपस,स्टुडेंट लोन jumps
By solomon
U.S. consumer borrowing unexpectedly climbed again in October as a jump in student loans offset the 26th consecutive decline in credit-card use.
Consumer credit outstanding increased at a seasonally adjusted annual rate of 1.7%, up by $3.4 billion to $2.4 trillion, a Federal Reserve report said Tuesday. The gain was the second in as many months following 19 straight losses. Economists surveyed by Dow Jones Newswires had predicted a $2 billion decline in October consumer credit.
The data Tuesday showed the October gain was driven by another big increase in student loans, a category that pushed up overall consumer credit in September by $1.2 billion. Originally the Fed reported a $2.1 billion increase in September borrowing.
The report on October borrowing showed revolving credit decreased $5.6 billion, or 8.4%, to $800.5 billion. The last time credit-card debt rose was August 2008.
About 8 million consumers stopped actively using credit cards over the past year, according to the credit-reporting group TransUnion. In a report Nov. 29, it said credit-card delinquencies continued declining amid tighter lending standards by banks.
The Fed report Tuesday said nonrevolving credit rose 6.8%, or $9 billion, to $1.6 trillion. The category includes loans for cars, tuition, and boats.
The consumer-credit report doesn’t include numbers on home mortgages and other real-estate-secured loans. But the data are important for the insight given into consumer behavior.
Tuesday’s report confirmed U.S. spending by consumers is modest, a trend that is restricting the economy from growing strongly out of recessions
U.S. consumer borrowing unexpectedly climbed again in October as a jump in student loans offset the 26th consecutive decline in credit-card use.
Consumer credit outstanding increased at a seasonally adjusted annual rate of 1.7%, up by $3.4 billion to $2.4 trillion, a Federal Reserve report said Tuesday. The gain was the second in as many months following 19 straight losses. Economists surveyed by Dow Jones Newswires had predicted a $2 billion decline in October consumer credit.
The data Tuesday showed the October gain was driven by another big increase in student loans, a category that pushed up overall consumer credit in September by $1.2 billion. Originally the Fed reported a $2.1 billion increase in September borrowing.
The report on October borrowing showed revolving credit decreased $5.6 billion, or 8.4%, to $800.5 billion. The last time credit-card debt rose was August 2008.
About 8 million consumers stopped actively using credit cards over the past year, according to the credit-reporting group TransUnion. In a report Nov. 29, it said credit-card delinquencies continued declining amid tighter lending standards by banks.
The Fed report Tuesday said nonrevolving credit rose 6.8%, or $9 billion, to $1.6 trillion. The category includes loans for cars, tuition, and boats.
The consumer-credit report doesn’t include numbers on home mortgages and other real-estate-secured loans. But the data are important for the insight given into consumer behavior.
Tuesday’s report confirmed U.S. spending by consumers is modest, a trend that is restricting the economy from growing strongly out of recessions
Tuesday, November 30, 2010
ग्लोबल economy
Global Economic Prospects
Key messages
The global recovery is moving into a more mature phase led by growing domestic demand.
* However, conditions in Europe may derail the recovery.
* A more rapid adjustment of fiscal policy would be better for developing countries.
* A decline in aid flows could have serious consequences for the poorest countries.
* More...
Global outlook summary table
A table summarizing the forecast. More detailed information is available here.
Debt crisis
So far, the uncertainty about the sustainability of fiscal positions in several high-income European countries (EU-5) has had limited impacts on developing countries. While stock markets have declined, spreads and credit default swaps for most countries have remained stable. So far industrial production and trade continue to expand rapidly. More...
Financial markets
Financial markets have recovered from their lows in 2009, but conditions remain tight and banks may be exposed to debt in EU-5 countries. Bond issuance declined sharply in May. International capital flows to developing countries are projected to reach about 3.5 percent of their GDP in 2012, up from 2.5 percent in 2009. See also the topical annex on Financial market developments. More...
Medium-term prospects
Growth prospects are very uncertain because of the situation in Europe. Nevertheless, developing countries are projected to lead the recovery with growth rates around 6 percent. High-income countries growth will accelerate from about 2-2.3 percent in 2010 to between 2.3 and 2,7 percent in 2012.
Regional annexes touch on prospects in:
* East Asia & the Pacific
* Europe & Central Asia
* Latin America & the Caribbean
* Middle-East & North Africa
* South Asia
* Sub-Saharan Africa
More...
Risks and policy impacts
Should the crisis in Europe worsen, global growth could be, lower by between as much as 0.7 percentage points and in the case of a crisis, a double-dip recession in high-income countries may not be avoided. An aggressive fiscal consolidation response would prove to be win-win for both high-income and developing countries. Long-term growth and poverty reduction in low-income countries could be affected if bilateral aid flows fall as they have during previous recessions. More...
Concluding remarks
Policy in high-income countries should focus on reducing the uncertainty surrounding the Greek debt issue. Growth in developing (and high-income) countries would benefit from a more rapid consolidation. Poverty reduction in low-income countries could be impeded if aid flows are cut and countries are forced to cut back on infrastructure and human capital investment. More...
Prospects for commodity markets
Prospects for inflation
Prospects for financial mark
Key messages
The global recovery is moving into a more mature phase led by growing domestic demand.
* However, conditions in Europe may derail the recovery.
* A more rapid adjustment of fiscal policy would be better for developing countries.
* A decline in aid flows could have serious consequences for the poorest countries.
* More...
Global outlook summary table
A table summarizing the forecast. More detailed information is available here.
Debt crisis
So far, the uncertainty about the sustainability of fiscal positions in several high-income European countries (EU-5) has had limited impacts on developing countries. While stock markets have declined, spreads and credit default swaps for most countries have remained stable. So far industrial production and trade continue to expand rapidly. More...
Financial markets
Financial markets have recovered from their lows in 2009, but conditions remain tight and banks may be exposed to debt in EU-5 countries. Bond issuance declined sharply in May. International capital flows to developing countries are projected to reach about 3.5 percent of their GDP in 2012, up from 2.5 percent in 2009. See also the topical annex on Financial market developments. More...
Medium-term prospects
Growth prospects are very uncertain because of the situation in Europe. Nevertheless, developing countries are projected to lead the recovery with growth rates around 6 percent. High-income countries growth will accelerate from about 2-2.3 percent in 2010 to between 2.3 and 2,7 percent in 2012.
Regional annexes touch on prospects in:
* East Asia & the Pacific
* Europe & Central Asia
* Latin America & the Caribbean
* Middle-East & North Africa
* South Asia
* Sub-Saharan Africa
More...
Risks and policy impacts
Should the crisis in Europe worsen, global growth could be, lower by between as much as 0.7 percentage points and in the case of a crisis, a double-dip recession in high-income countries may not be avoided. An aggressive fiscal consolidation response would prove to be win-win for both high-income and developing countries. Long-term growth and poverty reduction in low-income countries could be affected if bilateral aid flows fall as they have during previous recessions. More...
Concluding remarks
Policy in high-income countries should focus on reducing the uncertainty surrounding the Greek debt issue. Growth in developing (and high-income) countries would benefit from a more rapid consolidation. Poverty reduction in low-income countries could be impeded if aid flows are cut and countries are forced to cut back on infrastructure and human capital investment. More...
Prospects for commodity markets
Prospects for inflation
Prospects for financial mark
Tuesday, December 9, 2008
Thursday, June 5, 2008
the rich undergraduate
The rich undergraduate is a book that will change many things in you.
Is coming your way very soon.
by johnson solomon
Is coming your way very soon.
by johnson solomon
meet the real men with real ideas
Everyone Knows That Biotechs Explode Profits…
The Kind That Run As High As
867%,
But, Hardly Anyone Knows Where To Find The
“ Next Big One,” Or When It Will Pop
NOW YOU COULD KNOW EXACTLY WHICH ONE!
Because, America’s Super Wealthy Have Just Poured Nearly
Two Thirds of a Billion Dollars Directly Into One Ripe Baby Blue-Chip Biotech
Dear Friend,
For the next six minutes you need to forget about recessions and sub-primes. Instead, you must focus on today’s two forgotten Rs…
Rewards and riches …
Sudden riches, to be exact!
Because, today, while much of the investment world is busy making excuses, there’s one renowned authority who continues to deliver stunning results.
One of those is ready to drop into your lap right now…
Easy manna from heaven… ready to reward you with what history suggests are returns that could quickly run to 188% and 867%... then much, much higher in the months and years after that… even beyond 2,000%.
Yes, those are bodacious numbers – you’ll get no argument about that from here.
And, while normally you’d be right to think that it takes extraordinary risk for a shot at banking extraordinary returns such as these… this time, that simply doesn’t look to be the case.
Build Your Fortune Alongside These Billionaires
That’s why you need to immediately examine the small, genius-led biotech company that’s detailed in depth for you in this letter.
This small company has earned the full faith and backing of some of America’s richest investors, most successful investment bankers and biggest philanthropist… that’s right, philanthropist…
They’ve poured more than $630 million into this biotech since Sept. 30, 2007.
Among them are the The Bill and Melinda Gates Foundation, the Baker brothers, J.P. Morgan’s bank, John Granahan and Ned Johnson, to name just a few of the legends on board today.
And, while it’s nearly certain that you’ve heard and read about the majority of the super investors who are deep into this baby blue-chip biotech… there’s an even better chance that you’ve never heard about two of the major players of this group.
So, before you move on to discover the power-punch this small biotech packs… and meet the internationally respected authority who has uncovered this opportunity — and many others — for you, you need to take a minute to meet your new best friends…
They’re in up to their necks on this one.
Better still, that’s apparently how they like it. Because it seems they seldom, if ever, lose.
Why You Must Follow Two Fabulous Brothers
So, who are these brothers? Why must you follow them?
The short version is that one earned a Ph.D. in immunology from Stanford University. The other graduated from Harvard.
They are serial biotech investors. They are serial profit makers, as you’ll see.
Here’s what they’ve been up to since May of 2006. And, yes, they had a stinker in that time, but they both sit on its board, so it’s likely a winner waiting to happen.
What the brothers didn’t have to wait for, however were these quick profits.
And, now the famous brothers have jumped with both feet into the baby-blue bio.
By the way, just a bit later, you have the immediate opportunity to access a new Strategic Report about the baby blue chip biotech, plus five additional Strategic Reports on other fertile opportunities.
The biotech report is easy-to-read. It details why the brothers — the Baker brothers — should be your new best friends.
$53 Million Says The Bros. Are Right
Of course, you don’t have to get in as deep as the Baker Brothers, unless you have a spare $52.9 million lying around. Because that’s what the brothers paid for their initial stake in the baby blue chip.
And, it’s why you need to follow the brothers in.
As you’ve seen, these guys are winners.
On September 30 2007, they got down for 4,712,589 shares of the genius-run biotech.
That’s also the day The (Bill and Melinda) Gates Foundation plunked down $39 million for 3.5 million shares… J.P. Morgan Chase jumped in with $60 million for 5.3 million shares… Ned Johnson’s FMR Corp. peeled off $97.3 million for 8.6 million shares… and John Granahan’s eponymous company bought up $27 million.
They all paid $11.24…
The January Markets Have Done You A Major Favor…
The Biotech Brothers Took Advantage, TooThe great news is that today, you shouldn’t need to pay anywhere near $11.24... the price the masters of the universe paid.
Somewhere between $9.25 and $11 should be your target.
That’s because the fear that swept the markets in January punished the good and the bad alike.
And, while sometimes it’s hard to tell what’s just cheap (and probably should even be cheaper) and what’s a good stock that just got pounded… following the insiders shouldn’t lead you astray.
Because, when the markets pounded the baby-blue chip biotech the Baker Brothers were buyers… big time.
Between Jan. 18 and Jan. 28 this year the brothers went to town.
They bought 2.6 million additional shares for $24.1 million at an average price of $9.
So, the brothers’ track record insists that they’re not crazy. It does, however, suggest that anyone who doesn’t follow them is.
Long Term Is Where Your Real Action Lies
And, while the brothers’ many successes portend well for you in the short term… this opportunity is also fat with the potential for you to pile on the profits long-term.
It’s just the way good biotech deals work… as you’ll see in the Strategic Report that lays this one out clearly for you.
And that means, when you examine the report on this biotech please keep in mind that this company could end up like one of these.
2,381% – Medivation Inc. (MDVN)
$1.01 Jan. 2004 to $25.06 Oct 07 $4.40. March 2005 to $40.56 Jan. 2008 36 cents Aug. 2004 to $6.60 Jan. 2008 $5.62 March 2002 to $54.40 Jan. 2008 85 cents July 2002 to $18.80 Oct. 2007 $3.00 Aug 2003 to $75.20 Jan. 2008 $1.14 May 2005 to $13.84 Nov. 2007 Here’s What All Fuss Is About…
The Baby Blue Chip That’s Set To Explode!You’re going to read about this super biotech opportunity in-depth in a Strategic Report you can gain immediate access to today, along with several more special reports… but, here’s just a taste of why the potential is so great on this one.
New and brash, the baby blue chip biotech is already knocking its competitors aside… this genius-led biotech came public in 2001. Yet, it’s already established a fat pipeline of interesting and cutting-edge new cancer treatments.
The potential of these breakthrough cancer treatments has its competitors drooling.
The company’s research programs and new drugs have captured the interest of big players like Genentech, Bayer, Medimmune, ProGenics, PDL BioPharma and CuraGen.
That’s all because the baby blue chip’s drug candidates are aimed at treating cancers such as non-Hodgkins lymphomas, leukemia, multiple myeloma, lymphomas and solid tumors.
Sadly, As You May Well Know,
Cancer May Be An Unlimited MarketplaceCancer treatment is a huge and growing global market.
In fact, in the year 2000, the World Health Organization (WHO) reported that malignant tumors were responsible for 12% of the nearly 56 million deaths worldwide.
The WHO went on to report that in developed countries the probability of being diagnosed with cancer is more than twice as high as in developing countries.
But while cancer was once considered a Western disease, the WHO report highlights that more than 50% of the world’s cancer burden, in terms of both numbers of cases and deaths, already occurs in developing countries.
Bulls-Eye Drugs Are The Future…
The Possible Cancer CureThat puts the baby blue chip biotech on the forefront of the global drive to cure common cancers.
What distinguishes the genius-led company is that it has what might be the best pipeline of very promising products that are currently being tested in clinical trials.
In a crowded field, this biotech’s specialty may be THE hottest area in biotech-genetic research today.
That’s because it’s become a leader in monoclonal-antibody technology field…
And, yes, that’s a mouthful…
But, this isn’t fixing the engine on your snow blower or lawnmower… this isn’t even about everyday competencies like tuning your car, which you have to admit is way more complex – even impossible – than it was just 10 years ago.
This is the work of geniuses… the kind of work that you should be proud of… because you had a hand in creating a public education system that produced brilliant researchers such as those who work at this biotech.
And, while you could reap a financial reward from this cutting-edge work… either you or your family is in line to directly benefit from this research as well.
You see, the drugs this biotech is currently testing in clinical trials are creating success stories… and cancer remissions… and what look to be real cures.
Making Your Dream Real…
By Pushing the Dream of A Real Cancer Cure Closer To RealitySo, beyond the potential to deliver you – and the super investors – massive profits… it’s still fair to ask why is this important work? Why all the fuss?
The answer is actually pretty simple.
Researchers have been chasing this dream – to develop antibodies that kill cancer and leave healthy tissue alone – for three decades. Dozens of companies, hundreds of potential drugs have tried.
After all that time, the best they’ve been able to do is come up with drugs that do the job but have some real problems, too.
The best of those drugs are drugs like Avastin. It kills cancer cells, but its also kills healthy cells.
But, the baby blue chip biotech’s new drugs are as close to the dream as anyone has come up with yet. Its clinical tests hint – and you need to know that hint is the operative word here – that they might have made the dream real.
It’s why the Bill and Melinda Gates Foundation owns 5% percent of the company.
Because this biotech’s promising monoclonal-antibody drugs look as if they can successfully carry a targeted payload of toxin directly to tumor cells… nothing more.
That means the baby blue chip’s researchers may have cracked the code… a 30-year breakthrough.
But You Don’t Have To Take Our Word…
The Marketplace Is Already SpeakingThis breakthrough class of drugs are so promising that another biotech giant is paying all costs for Phase II trials so the baby blue chip biotech can put its money to work on other drugs it has in development.
That means the biotech can keep its cash-burn-rate under control so that it will live long enough to generate real profits – as many young biotechs do not.
In fact, the company’s financial reports reveal why so many top investors and competitors are so fervently in its corner.
After all, this company has rapidly expanded from a paltry $100,000 in sales in 2000 to $10 million in sales last year. Now, industry analysts and the company agree that it should double sales this year and reach nearly $30 million next year… and explode…
That fast rate of expansion means other money has started to roll in as well…in October it was a $1.5 million payment from a collaborator, in December a $12 million milestone payment from another…
Then in January it attracted another $4 million and news that its entitled to as much as $800 million for meeting future milestones along with a stream of royalties starting between 13% and 16% and going higher when its product is safely on the market
That makes this biotech a total rarity…
A small biotech that can stand up for itself… that’s why it’s a baby blue chip…
For while it’s financial mission is to greatly reward all its investors, its research mission is so noble that it’s hard to find anyone in the industry that isn’t in its corner.
Wait Until You Discover Who Uncovered The Biotech For You!
So, you’ve seen that the masters of the universe are shouldering each other out of the way to invest in this one small biotech.
You’ve seen why.
The company looks like it may have solved an ages-old problem with a new class of cancer treatment drugs.
And, by now, you likely realize the awesome financial ramifications this means for you.
So let me share a secret with you… okay, maybe it’s more like a surprise.
Because, certainly by now you suspect that the Strategic Report that lays this opportunity out for you in such an easy to understand manner must come from some well-known biotech speculator… someone who loses as much as he wins.
But, nothing could be farther from the truth.
Tens Of Thousands Of Readers Have
Trusted This Investment Authority For YearsAnd, that may be the most compelling reason behind why this opportunity deserves your immediate attention.
Because, not only is this opportunity as real and ripe as it can be – but it comes to you directly from a most unlikely source… a renowned value investing authority…
One of America’s most trusted, and skeptical, investment authorities.
A Cleanup Hitter On A Championship Lineup
Look, you and I both know that this modern media world is one that thrives on hype.
So when I make a bold statement, such as, “this baby blue chip biotech comes to you from a renowned and trusted investment authority,” you have the absolute right to take pause.
But, just you like you, after a couple of decades in my career I too became a real good judge of talent.
By the way, I am MaryEllen Tribby, the CEO of Early To Rise and the Executive Publisher of Investor’s Daily Edge.
As you might know, ETR and IDE have hundreds of thousands of readers around the world. We’re also an affiliate company of Agora Inc., the world’s leading financial newsletter publisher.
As for my bona fides: I started earning my reputation as an astute judge of investing talent during the years I managed a large division of Forbes. Later, I served as President of Weiss Research, the global investment house.
And, as I am sure you are aware – in this business, you’re only as good as your best guru.
When I find an expert who can deliver market-beating investment ideas, over and over again, that person is like gold. I’ve been fortunate to work with a few people like that.
And, that’s what makes the authority you are about to meet even more rare.
You see, while she has proven to be one of the most successful stock pickers in the world, her real strength is that she is a total straight shooter… no political baggage… no hidden agenda.
So, while you’ll likely make a lot of money, what you’re really going to like about Lynn Carpenter is that hers is an authoritative, sane voice that slices through an investment world that has become as noisy as the Beatles on Ed Sullivan, or a Led Zeppelin concert.
Yes, You Have The Rare Chance Today To
Align Yourself With That Lynn CarpenterThis is the same Lynn Carpenter who during the last market crisis, the one from 2000 to 2003, positioned investors so well that in the ensuing years they knocked down more than 19 winners that exceeded all expectations… they emerged from the dark days as some of the few winners.
Talk about taking advantage of economic pain… that’s just what you need now!
And you thought value investing was boring, huh?
And, I’ll prove that to you on just a second when you get a look at just some of the hefty gains Lynn’s readers booked the last time the markets went south.
Then, I think you’ll agree that there’s nothing quite like cashing in a string of winners all while lowering your risk to unheard of levels.
Cutting Risk To The Bone Doesn’t
Have To Mean Sacrificing Powerful ProfitsAnd, as you’re about to see, Lynn may know how to deal with the worst of Wall Street… but she also knows the very best about you.
And, as many of you know, Lynn has proved this time and time again during her years as editor of the world-famous Fleet Street Letter and as an Investment Advisory Panelist for The Oxford Club.
Today, Lynn is the founder/editor of the Rising Tide Letter. Day-in and day-out, for readers across the globe, Rising Tide is an immediate source of investment sanity and steady returns.
Lynn is rare in the financial world because she will be the first to admit that your instincts are pretty much always right… it’s just the information you’re getting that’s usually so wrong.
She knows that in every other aspect of your life you set your own agenda… that you strive to be independent, practical, even brave… and that you can smell BS a mile away.
And, Lynn knows these are traits that will make you a great investor… if only you were allowed a chance.
In just a second you are going to see how Lynn’s powerful methods can super-charge your goals… you’ll see a sample of her current track record… and one from 2000 to 2003, the last time the economy was in the dumps… and most people had a difficult time navigating the markets.
You Will Join The Ranks That Sing Lynn’s Praise
But, so you’ll know I am not over-hyping Lynn by referring to her as in internationally respected investment authority, here are just a few examples of what you’ll find when you search for Lynn Carpenter in Google… doesn’t everybody use the Google search engine today?
From (of all publications) The Canadian Mining News:
“Anyone can recommend stocks, but [Lynn Carpenter] recommends outstanding companies — ones specifically chosen to help subscribers steadily increase their wealth in all markets. No fads, no hype… unbiased research and common sense, and all written clearly and enjoyably for smart investors who like to make their own decisions. Best of all, [she] tracks their picks, so readers are never left guessing.”
From Siu-Yee Ng in Taipan:
“Those who attended the Oxford Club’s Investment University conference in March cashed in on a 129% option winner just 10 days after Lynn gave it to them. That’s nothing new for Lynn, whose world-renowned service delivered 51 winners that ranged between 57% and 299% in [2001-2003] alone.”
From the pages of an international bestseller:
“I particularly like Lynn Carpenter… who is a contrarian value investor…” John Mauldin in Bullseye Investing, page 384.
That New York Times best-selling author John Mauldin yet again, from a weekly column:
“ Lynn Carpenter, is a no-nonsense value oriented stock picker with a solid track record… I have always been a big fan…”
A funny one from New York Times best-selling author Bill Bonner, who really needs no introduction:
“Jim Davidson was there. So was Lynn Carpenter. I have known both of them from childhood. We all failed to grow up together.”
From Agora Wealth:
“Lynn commanded attention as the editor of The Fleet Street Letter from 1999-2004 when she averaged a 15% gain per year - even while the S&P was losing 40%. During this time, she discovered how to use her scientific approach to take advantage of quick, leveraged profit opportunities.”
From the Oxford Club’s Investment U
“Lynn Carpenter is the former editor of Fleet Street. She struck out on her own and has a new publication called Rising Tide. I loved her opening line…
‘“Have you ever noticed that there's one word that you never hear at these kinds of conferences? Money. When we talk about investments and assets and gains and losses - we're talking about your money! I never forget that. Which is why I'm so committed to identifying value.’
“Lynn is a committed value investor. Bull markets always end, she warns, but investing in value is insurance against losing when it does. You can always find a good value in any kind of market - and it will tend to remain a value despite the overall market conditions.
“‘Value means value,’ she states. Which, she adds, doesn't mean she's looking for cheap stocks - a common misperception of value as only being low cost.”
Wow!
That should be enough for you… though I have a file of others including positive comments from Tholius Investments, Christopher Mayer, The Ludwig von Mises Institute and even another from the Canadian Mining News (who knew, huh?).
But, this gives you a good idea of what the world thinks of Lynn Carpenter.
Not Everyone Will Avoid the Rocks, But You Could
And, why shouldn’t they think highly of her?
Lynn has helped a lot of people make a lot of money… particularly when times are bad.
Just look at the partial list of winners she generated back in 2000 to 2003, during the last recession.
Stunning.
I know many of you remember these because you were part of the tens of thousands of Fleet Street subscribers at the time.
Readers who sailed through the recession if they followed Lynn’s recommendations such as H&R Block, which flew 138% from December 2000 to March 2002 – in the heart of market swoon.
Recession Busters
For The Oxford Club:
You’re Right!
Investing is About “ What Have You Done For Me Lately ”Yes, that’s all yesterday’s news.
But, did you honestly think that an authority who could whip a recession wouldn’t sail though the easy years?
Here’s just a sample of Lynn’s most current work (the stuff she can show you without giving away the farm)… from the Rising Tide Letter.
Your Key To Steady, Sustained Profit Potential and Low Risk
In a world that filled with every imaginable exotic investment play… a world where if you trade online it’s possible to lose money about 20 hours a day… you deserve a rock in your corner.
That’s why relying on Lynn Carpenter is a must for your investment survival.
And why the upshot of all this is that Lynn Carpenter… like most of the world’s gifted investors… is a value investor.
And, yes, I know when you hear the term value investing you imagine scrawny old six and seven percent returns… but as you’ve seen nothing could be farther from the truth.
In the hands of a master such as Lynn Carpenter, value means companies that are set to take off… turnarounds… overlooked… or beaten up for no good reason.
These are real companies with real profits that are just set to explode. You don’t want to miss out… especially on the next 18 months.
That’s why it’s so important that you take a moment today to subscribe to Lynn’s Rising Tide Letter.
It’s the tide that floats all boats.
The Absolute Power To Rule Your Financial Destiny
And that’s why I have arranged such an outstanding value for you today… it’s one that matches the extraordinary biotech opportunity that’s on the table for you right now.
Please accept my invitation for you to subscribe to the Rising Tide Letter today, at the deeply discounted rate of $99 for one year...
And, when you subscribe to the Rising Tide Letter today, I’ll lock in your subscription rate in for life. It will never increase, no matter how wealthy you may become or how much more successful Lynn and Rising Tide become.
Yes, You Could Make A Lot of Money… But Rising Tide Is Also A Great Way to Always Have Someone Covering Your Back
You should need no further inducement to subscribe.
But, when you subscribe today – along with the Strategic Report that details the baby blue chip biotech – you’ll also gain immediate access to these five vital Rising Tide Letter Strategic Reports…
WHEN THE HAMMER FALLS: How to Rip Your Share of Easy Profits from the Market’s Wreckage
The subprime mortgage mess devastated whole industries and spread to the broad market. Where do you invest now to make the most of the opportunities that have quietly popped up… after an exhaustive search, Lynn Carpenter’s Rising Tide Letter has uncovered seven companies that should thrive in the current market . This is as timely a report as you’ll likely ever read.THE TWO BEST MEDICAL STOCKS FOR 2008 and BEYOND
Sadly, recession or good times, people will always get sick or hurt. In this timely report Lynn Carpenter shows you just where to find 2008’s two most potentially explosive medical stocks.
EMBRACE THE BEAR: Waiting for the Bull Could Cost You a Fortune
The market is bearish a third of the time. Can you handle it? Even in “bull years,” down legs spoil the party—the news is glum, losses mount, and investors are running for cover. But not everyone. Find out the secret: bears really know what to do when the market is sinking: sell, sit or buy? Doing the right thing will multiply your fortune twice as fast.
IT’S NOT WHAT YOU’VE BEEN TOLD: The Myths and Truths of Value Investing—The Value Primer.
Every time a bubble bursts, value investors can hardly contain their smiles. That’s because they know it’s possible to make real money in any market. They’re cashing in on steady to even embarrassingly good profits because, guided by value masters such as Lynn Carpenter, value investors buy low… they don’t buy shoddy. In this ripped-from-the-headlines report, you’ll discover just where growth fits into the value quotient… the crippling lies about price that academics prove time and again— only to see it fails miserably in real life, real money situations. The right P/E ratio for a grocery store and a software company… and the essential mission that marks real value. In other words, you’ll discover why value rules in any market.
And… The Baby Blue Chip Biotech
Also, don’t forget, that along with these five powerfully profitable Strategic Reports, your subscription to the Rising Tide Letter comes with immediate access to the Strategic Report you’ll want to read first…
THE MOST IMPORTANT BIOTECH EVER – One company looks like it may have solved one of cancer treatment’s biggest riddles – how to kill only the targeted cancer cell and leave the healthy cells alone. This is breakthrough stuff. It’s why some of America’s top super-wealthy investors have poured more that two-thirds of a billion dollars into this one baby blue chip biotech in the past few months alone. This very well could be the one… the cancer cure company… maybe one of the most important companies ever.
The Whole Megillah
So to review – for your low annual subscription rate of $99 you’ll receive…
Frankly that’s a lot and should be more than enough for you to subscribe today
The Very Best Just for You
There you have it. The monthly newsletters, weekly email alerts, the six extra email columns a month, the five Strategic Reports and immediate access to the baby blue chip biotech Strategic Report.
It’s the very best I can do for you.
And, frankly, it’s a lot. Especially when you consider the low cost of your fully guaranteed Rising Tide Letter subscription, and the fact that your subscription rate will never increase.
This should be one of the easiest, most potentially profitable decisions you’ll make this year. Maybe ever!
Accept Your Fully Guaranteed, No-Risk Invitation, Today!
I would prefer to think that serious investors, who understand the complete value of what the Rising Tide Letter offers them, will subscribe today.
But, to show you how serious I am, I’ll make you this simple and unconditional guarantee.
If you’re not totally satisfied with the Rising Tide Letter for any reason, during your first 30 days, simply let me know in writing via e-mail, fax or letter and I’ll refund 100% of your subscription.
Anytime after that, I’ll cheerfully and quickly refund the balance of months remaining in the term of your subscription, should you become disenchanted for any reason.
And, yes, in the unlikely event this happens, you will keep all six Strategic Reports that come with your subscription.
Finally… The Success, Respect and Prosperity That You Deserve
This superb offer is yours for one reason.
I want you to be the rare individual who actually makes it big. I want you to be the big dog at any investment conference you attend… the hold-their-feet-to-the-fire, confident moneymaker.
This is your path when you accept your subscription to the Rising Tide Letter, today.
So, I urge you to immediately accept your fully guaranteed subscription to the Rising Tide Letter.
SO, YES!
This Could Be The One Company That Changes Your DestinyBecause, subscribing today is the fastest… perhaps only way… you’ll learn about the baby blue chip biotech tech that Lynn Carpenter has found for you, along with the other top opportunities she details for you each month in the pages of the Rising Tide Letter and in the complimentary Strategic Reports you can gain immediate access to today.
The biotech is a company that has what every investor loves to hear…
People clamoring to get their hands on a product that never before existed…
A groundbreaking product that is only made by one company…
It’s even better for humanity than other one-product wonders such as Apple’s iPod, which drove Apple’s shares from $6.36 in April 2003 to $143.85 in August 2007… or Google’s search engine which drove its shares from $101 in August 2004 to $555 in August 2007…
In short, it’s your rare opportunity to own what could be one of the most important companies of our time.
So, needless to say, this is a company that could potentially make you rich.
I’m talking, depending on your stake, tens of thousands, hundreds of thousands… even millions rich.
So, I look forward to hearing from you today. And, I look forward to your future comments about how pleased you are with Lynn and the Rising Tide Letter.
Thank you for sharing your valuable time.
Sincerely,
MaryEllen Tribby
Executive Publisher, Rising Tide Letter
February 2008P.S. I would like to share something with you. It’s about the real person you’re set to align yourself with – the real Lynn Carpenter. I came across this quite by accident the other day. It was published in Bill Bonner’s Daily Reckoning on Sept. 19, 2001… a difficult time for all Americans. But, it’s how we act in times such as those that distinguish the best of us. This should make you very proud to know Lynn.
“Lynn Carpenter recommended buying put options on Morgan Stanley about two weeks before the World Trade Center tragedy. Those who followed her advice more than doubled their money.
“Yet, immediately after trading resumed on September 17th, Lynn apologetically urged her readers to close the position and to seek no additional profit from Morgan Stanley's misfortune. Lynn says readers e-mailed to praise her character. They're discovering what the rest of already know... Lynn is a woman of the highest integrity.”
P.P.S. During a recent phone call with Lynn, she made a smart-assed remark about all the gold scamsters in the market today. I said, “Sounds like a good article.” The next day, Lynn did better than that. She delivered to my desk a Strategic Report that more than detailed her concerns. I want to send it to you right now, when you subscribe to the Rising Tide Letter. It’s called:
GOLDEN LIES – There’s a whole sector waiting to make suckers out of goldbugs. The lies are outrageous… the truth is hard to find. In this report Lynn Carpenter lays open the gold market for you and the fools who are trying to snatch your wallet. There is also a clearly stated case for the best gold play on the market today… it will surprise the heck out of you.
Subscribe to:
Posts (Atom)
